自引率: 2.5%
被引量: 1389
通过率: 暂无数据
审稿周期: 2.88
版面费用: 暂无数据
国人发稿量: 28
投稿须知/期刊简介:
Cancer Biology & Medicine为季刊，国内外公开发行，由中国科学技术协会主管、中国抗癌协会主办，主编为我国著名肿瘤学专家郝希山院士。作为中国抗癌协会国内外学术交流的重要媒介，以肿瘤临床医师、基础研究人员、相关交叉学科专业人员及医学生为读者对象，向国际学术界展示中国肿瘤防治研究成果，向国内肿瘤学相关专业人员介绍全球肿瘤学前沿进展。刊登稿件范畴：肿瘤表观遗传学、肿瘤干细胞生物学、分子与临床免疫学、肿瘤预防与流行病学、肿瘤标志物、肿瘤影像学、肿瘤临床试验、肿瘤靶向治疗、肿瘤生物治疗、肿瘤个体化医学与多学科综合治疗。设有述评、综述、论著、临床指南、会议报道、病例报告、读者来信等栏目。 Cancer Biology & Medicine is a peer-reviewed open-access journal published by the Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics: ● Cancer genetics ● Cancer and stem cell biology ● Molecular and clinical immunology ● Cancer prevention and epidemiology ● Cancer biomarkers ● Radiation oncology ● Oncology clinical trials ● Mechanisms of drug sensitivity and resistance ● Targeted therapy and immunotherapy ● Multidisciplinary treatment and personalized medicine
期刊描述简介:
Cancer Biology & Medicine is a peer-reviewed open-access journal published by the Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics: ● Cancer genetics ● Cancer and stem cell biology ● Molecular and clinical immunology ● Cancer prevention and epidemiology ● Cancer biomarkers ● Radiation oncology ● Oncology clinical trials ● Mechanisms of drug sensitivity and resistance ● Targeted therapy and immunotherapy ● Multidisciplinary treatment and personalized medicine
-
Evolving molecular subtyping of breast cancer advances precision treatment.
被引量：- 发表：2024
-
SETD2 in cancer: functions, molecular mechanisms, and therapeutic regimens.
被引量：- 发表：2024
-
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer.
被引量：- 发表：1970
-
The current role of dendritic cells in the progression and treatment of colorectal cancer.
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide. Dendritic cells (DCs) constitute a heterogeneous group of antigen-presenting cells that are important for initiating and regulating both innate and adaptive immune responses. As a crucial component of the immune system, DCs have a pivotal role in the pathogenesis and clinical treatment of CRC. DCs cross-present tumor-related antigens to activate T cells and trigger an antitumor immune response. However, the antitumor immune function of DCs is impaired and immune tolerance is promoted due to the presence of the tumor microenvironment. This review systematically elucidates the specific characteristics and functions of different DC subsets, as well as the role that DCs play in the immune response and tolerance within the CRC microenvironment. Moreover, how DCs contribute to the progression of CRC and potential therapies to enhance antitumor immunity on the basis of existing data are also discussed, which will provide new perspectives and approaches for immunotherapy in patients with CRC.
被引量：- 发表：2024
-
Global, regional, and national burden of early-onset gastric cancer.
The burden of gastric cancer (GC) across different age groups needs updating. We determined the GC global, regional, and national burden profiles and changes in incidence for 3 sequential 5-year intervals from 2003 to 2017. The latest incidence and mortality estimates of GC from 185 countries and regions were extracted from the GLOBOCAN 2022 database. The 5-year interval age-standardised incidence rates (ASIRs) were evaluated using cancer registry data from volumes X-XII of the Cancer Incidence in Five Continents (CI5). Correlation analysis was used to evaluate the relationship between ASIR or the age-standardised mortality rate (ASMR) and the Human Development Index (HDI). There was an estimated global 968,000 new GC cases and 660,000 deaths in 2022, with male predominance. GC ASIRs and ASMRs were 9.2 and 6.1 per 100,000 persons, respectively. East Asia had the highest burden, with 53.8% of cases and 48.2% of deaths among all geographic regions. There was a significant correlation between ASIR and HDI. Over three 5-year intervals from 2003 to 2017, the incidence of GC notably decreased in most countries but peaked at 2008-2012 in New Zealand, Turkey, and South Africa. Several countries in Europe, Oceania, and America suggest an increasingly concerning trend among younger individuals, especially females. GC is a significant health issue, especially among males and in geographic regions with an HDI, such as eastern Asia. While the incidence of GC is decreasing in many countries due to prevention efforts and improved treatments, a rising trend persists among younger individuals. Comprehensive prevention strategies tailored to different age patterns are clearly needed.
被引量：- 发表：2024
